Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5017059 | 0.86 | BBOX1 (0.33) | — | |
| Tetrylammonium SCHEMBL5013736 | 0.85 | — | — | |
| Oxalic Acid SCHEMBL5015081 | 0.80 | ALDH1A1 (0.31) | — | |
| Tetrylammonium SCHEMBL5015099 | 0.79 | ALDH1A1 (0.33) | — | |
| Tetrylammonium SCHEMBL5022910 | 0.78 | MAPT (0.31) | — | |
| Tetrylammonium SCHEMBL5015057 | 0.78 | — | — | |
| Tetrylammonium SCHEMBL5022979 | 0.78 | MEN1 (0.34) | — | |
| Tetrylammonium SCHEMBL5015124 | 0.77 | — | — | |
| Tetrylammonium SCHEMBL5013722 | 0.76 | TSHR (0.32) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL5014690 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8652682-B2 | Ionic compound, electrolytic solution, electrochemical device, and battery | SONY CORPORATION (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20080118845-A1 | IONIC COMPOUND, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, AND BATTERY | SONY CORPORATION (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080118845-A1 | IONIC COMPOUND, ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, AND BATTERY | CA2, DUOX2, OTC | TSHR 2127/4885NFKB1 2548/4885KCNA1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.